{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:14Z","timestamp":1786121174219,"version":"build-2736575974"},"reference-count":264,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C16\/24\/012"],"award-info":[{"award-number":["C16\/24\/012"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["G.0316.25N"],"award-info":[{"award-number":["G.0316.25N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["G.0591.23N"],"award-info":[{"award-number":["G.0591.23N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004497","name":"KU Leuven Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.autrev.2026.104120","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:05:15Z","timestamp":1781201115000},"page":"104120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antigen-specific tolerance therapies in type 1 diabetes: Disease-specific promises meet stage-specific challenges"],"prefix":"10.1016","volume":"25","author":[{"given":"A.","family":"Wouters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gysemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104120_bb0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1152\/physrev.00003.2010","article-title":"Type 1 diabetes: etiology, immunology, and therapeutic strategies","volume":"91","author":"van Belle","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.autrev.2026.104120_bb0010","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/S0140-6736(25)01438-2","article-title":"The future of type 1 diabetes therapy","volume":"406","author":"Ziegler","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104120_bb0015","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1007\/s00125-015-3761-y","article-title":"Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes","volume":"58","author":"Van Dalem","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00125-019-4822-4","article-title":"Beta cells in type 1 diabetes: mass and function; sleeping or dead?","volume":"62","author":"Oram","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0025","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/db25-0326","article-title":"Loss of insulin-positive cell clusters precedes the decrease in islet frequency and \u03b2-cell area in type 1 diabetes","volume":"74","author":"Drotar","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0030","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging Presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb0035","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0040","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00125-018-4786-9","article-title":"Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis","volume":"62","author":"Perdigoto","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0045","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2337\/db13-0236","article-title":"Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled prot\u00e9g\u00e9 trial","volume":"62","author":"Hagopian","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0050","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0055","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0060","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/db11-0674","article-title":"Rituximab selectively suppresses specific islet antibodies","volume":"60","author":"Yu","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0065","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104120_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70074","article-title":"Subcutaneous abatacept in new onset type 1 diabetes: clinical and immunological effects","volume":"41","author":"Jerram","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.autrev.2026.104120_bb0075","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(25)01674-5","article-title":"Minimum effective low dose of antithymocyte globulin in people aged 5&#x2013;25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial","volume":"406","author":"Mathieu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104120_bb0080","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.autrev.2026.104120_bb0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1084\/jem.20182287","article-title":"Taming autoimmunity: translating antigen-specific approaches to induce immune tolerance","volume":"216","author":"Carballido","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5415\/apallergy.0000000000000128","article-title":"Immunological mechanisms of tolerance: central, peripheral and the role of T and B cells","volume":"13","author":"Meng","year":"2023","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.autrev.2026.104120_bb0095","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MED.0000000000000649","article-title":"Novel delivery mechanisms for antigen-specific immunotherapy","volume":"28","author":"Neef","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.autrev.2026.104120_bb0100","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db23-0387","article-title":"Increased frequency of the HLA-DRB1*04:04-DQA1*03-DQB1*03:02 haplotype among HLA-DQB1*06:02\u2013positive children with type 1 diabetes","volume":"73","author":"Ilonen","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11892-011-0223-x","article-title":"Genetics of the HLA region in the prediction of type 1 diabetes","volume":"11","author":"Noble","year":"2011","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.autrev.2026.104120_bb0110","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ng1197-350","article-title":"Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. The IMDIAB Group","volume":"17","author":"Bennett","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2026.104120_bb0115","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/j.cell.2025.02.018","article-title":"Genetic protection from type 1 diabetes resulting from accelerated insulin mRNA decay","volume":"188","author":"van Tienhoven","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104120_bb0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3892\/br.2024.1770","article-title":"Viruses as a potential environmental trigger of type 1 diabetes mellitus (review)","volume":"20","author":"Alves Abrantes","year":"2024","journal-title":"Biomed Rep"},{"key":"10.1016\/j.autrev.2026.104120_bb0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41577-023-00911-8","article-title":"A guide to thymic selection of T cells","volume":"24","author":"Ashby","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see (and don\u2019t see)","volume":"14","author":"Klein","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coi.2013.10.011","article-title":"The central role of antigen presentation in islets of Langerhans in autoimmune diabetes","volume":"26","author":"Calderon","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0140","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/cei.12672","article-title":"CD4 T cell differentiation in type 1 diabetes","volume":"183","author":"Walker","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0145","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/35100512","article-title":"Cross-presentation in viral immunity and self-tolerance","volume":"1","author":"Heath","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1084\/jem.178.1.87","article-title":"Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice","volume":"178","author":"Rapoport","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.974864","article-title":"Variable frequencies of peripheral T-lymphocyte subsets in the diabetes spectrum from type 1 diabetes through latent autoimmune diabetes in adults (LADA) to type 2 diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0160","first-page":"312","article-title":"Th1\/Th2 cytokines in type 1 diabetes: relation to duration of disease and gender, Indian","volume":"20","author":"Vaseghi","year":"2016","journal-title":"J Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104120_bb0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2017.00208","article-title":"Overlooked mechanisms in type 1 diabetes etiology: how unique costimulatory molecules contribute to diabetogenesis","volume":"8","author":"Wagner","year":"2017","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.autrev.2026.104120_bb0175","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.4049\/jimmunol.170.4.1649","article-title":"Th1 and Th2 pancreatic inflammation differentially affects homing of islet-reactive CD4 cells in nonobese diabetic Mice1","volume":"170","author":"Hill","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2003","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0185","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/cdd.2009.165","article-title":"The role of perforin and granzymes in diabetes","volume":"17","author":"Thomas","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.autrev.2026.104120_bb0190","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/icb.2015.89","article-title":"Perforin facilitates beta cell killing and regulates autoreactive CD8+ T-cell responses to antigen in mouse models of type 1 diabetes","volume":"94","author":"Trivedi","year":"2016","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0195","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2337\/diabetes.54.5.1407","article-title":"Functional defects and the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes","volume":"54","author":"Brusko","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0200","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nri1714","article-title":"Follicular B helper T cells in antibody responses and autoimmunity","volume":"5","author":"Vinuesa","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1450366","article-title":"The role of B cells in the pathogenesis of type 1 diabetes","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1450366","article-title":"The role of B cells in the pathogenesis of type 1 diabetes","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0215","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4049\/jimmunol.1701717","article-title":"Anti-insulin B cells are poised for antigen presentation in type 1 diabetes","volume":"201","author":"Felton","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0220","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.4049\/jimmunol.1202104","article-title":"Tolerant anti-insulin B cells are effective APCs","volume":"190","author":"Kendall","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0225","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000041613","article-title":"Unraveling the role of macrophages in diabetes: impaired phagocytic function and therapeutic prospects","volume":"104","author":"Rong","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2026.104120_bb0230","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0235","doi-asserted-by":"crossref","first-page":"14929","DOI":"10.1038\/s41598-022-19031-9","article-title":"Changes of macrophage and CD4+ T cell in inflammatory response in type 1 diabetic mice","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104120_bb0240","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2249.2008.03860.x","article-title":"Analysis of islet inflammation in human type 1 diabetes","volume":"155","author":"Willcox","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122146","article-title":"Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes","volume":"3","author":"Vecchio","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2026.104120_bb0250","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.imbio.2018.11.010","article-title":"Reactive oxygen species (ROS) in macrophage activation and function in diabetes","volume":"224","author":"Rendra","year":"2019","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2026.104120_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690379","article-title":"Oxidative stress leads to \u03b2-cell dysfunction through loss of \u03b2-cell identity","volume":"12","author":"Leenders","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1275316","article-title":"Footprint of pancreas infiltrating and circulating immune cells throughout type 1 diabetes development","volume":"14","author":"Bruggeman","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.autrev.2026.104120_bb0265","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/cei\/uxac093","article-title":"Neutrophils in autoimmunity: when the hero becomes the villain","volume":"210","author":"Bissenova","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nm.3042","article-title":"Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes","volume":"19","author":"Diana","year":"2013","journal-title":"Nat Med"},{"issue":"812","key":"10.1016\/j.autrev.2026.104120_bb0275","article-title":"Diabetes-associated neutrophil NETosis: pathogenesis and interventional target of diabetic complications","volume":"17","author":"Zhu","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.930553","article-title":"The contribution of neutrophils and NETs to the development of type 1 diabetes","volume":"13","author":"Petrelli","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0285","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.156.10.3602","article-title":"T cell suppression in transplantation tolerance through linked recognition","volume":"156","author":"Davies","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0290","article-title":"Short Report: CAR Tregs mediate linked suppression and infectious tolerance in islet transplantation","author":"Wardell","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.autrev.2026.104120_bb0295","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.2337\/dc13-0199","article-title":"Infliximab in the treatment of Crohn disease and type 1 diabetes","volume":"36","author":"Timper","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb0300","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/13543784.2020.1727885","article-title":"CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes","volume":"29","author":"Rachid","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2026.104120_bb0310","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13238-015-0164-2","article-title":"Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies","volume":"6","author":"Wang","year":"2015","journal-title":"Protein Cell"},{"key":"10.1016\/j.autrev.2026.104120_bb0315","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2567.2001.01335.x","article-title":"Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?","volume":"104","author":"Peakman","year":"2001","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2026.104120_bb0320","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltab009","article-title":"Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity","volume":"1","author":"Richardson","year":"2021","journal-title":"Immunother Adv"},{"key":"10.1016\/j.autrev.2026.104120_bb0325","first-page":"781","article-title":"Intestinal mucosal tolerance and impact of gut microbiota to mucosal tolerance","volume":"5","author":"Chistiakov","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.autrev.2026.104120_bb0330","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4161\/hv.27332","article-title":"Recent progress in adjuvant discovery for peptide-based subunit vaccines","volume":"10","author":"Azmi","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.autrev.2026.104120_bb0335","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41541-021-00418-0","article-title":"\u201cworld in motion\u201d - emulsion adjuvants rising to meet the pandemic challenges","volume":"6","author":"O\u2019Hagan","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.autrev.2026.104120_bb0340","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41591-020-0753-3","article-title":"Engineered immunogen binding to alum adjuvant enhances humoral immunity","volume":"26","author":"Moyer","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0345","article-title":"Self-assembled peptides: a new generation of vaccine adjuvant platform","volume":"13","author":"Zhang","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.autrev.2026.104120_bb0350","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1073\/pnas.1107941108","article-title":"Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88","volume":"108","author":"Seubert","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104120_bb0355","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104120_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.633776","article-title":"A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications","volume":"9","author":"Qin","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0365","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/14760584.2023.2282065","article-title":"Have mRNA vaccines sentenced DNA vaccines to death?","volume":"22","author":"Cagigi","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.autrev.2026.104120_bb0370","article-title":"DNA vaccines as promising immuno-therapeutics against cancer: a new insight","volume":"15","author":"Shariati","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0375","series-title":"Pharmaceuticals from Microbes","first-page":"39","article-title":"Live-attenuated bacterial vectors for delivery of mucosal vaccines, DNA vaccines, and cancer immunotherapy","volume":"26","author":"Kumar","year":"2019"},{"key":"10.1016\/j.autrev.2026.104120_bb0380","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21315\/mjms2024.31.6.2","article-title":"Live attenuated bacterial vectors as vehicles for DNA vaccine delivery: a mini review","volume":"31","author":"Eng","year":"2024","journal-title":"Malays J Med Sci"},{"key":"10.1016\/j.autrev.2026.104120_bb0385","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","article-title":"Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104120_bb0390","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1083\/jcb.201502074","article-title":"A bacterial type III secretion-based protein delivery tool for broad applications in cell biology","volume":"211","author":"Ittig","year":"2015","journal-title":"J Cell Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0395","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3389\/fmicb.2018.02100","article-title":"Genetic engineering of Lactococcus lactis co-producing antigen and the mucosal adjuvant 3\u2032 5\u2032- cyclic di adenosine monophosphate (c-di-AMP) as a design strategy to develop a mucosal vaccine prototype","volume":"9","author":"Quintana","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.autrev.2026.104120_bb0400","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3389\/fimmu.2017.01961","article-title":"Lactococcus lactis as a versatile vehicle for tolerogenic immunotherapy","volume":"8","author":"Cook","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0405","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fimmu.2018.00230","article-title":"Nanoparticles for the induction of antigen-specific immunological tolerance","volume":"9","author":"Kishimoto","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0410","article-title":"Nanoparticle-based drug delivery systems for induction of tolerance and treatment of autoimmune diseases","volume":"10","author":"Li","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.autrev.2026.104120_bb0415","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104120_bb0420","first-page":"1","article-title":"Liposomes as adjuvants and vaccine delivery systems","volume":"16","author":"Tretiakova","year":"2022","journal-title":"Biochem (Mosc) Suppl Ser A Membr Cell Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0425","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1080\/14760584.2023.2274479","article-title":"Vaccine approaches for antigen capture by liposomes","volume":"22","author":"Zhou","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.autrev.2026.104120_bb0430","article-title":"A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens","volume":"48","author":"Almenara-Fuentes","year":"2023","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.autrev.2026.104120_bb0435","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.it.2020.11.001","article-title":"Tolerogenic dendritic cells in autoimmunity and inflammatory diseases","volume":"42","author":"Morante-Palacios","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0440","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fimmu.2018.01169","article-title":"Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and Neuromyelitis Optica from preclinical to clinical trials","volume":"9","author":"Fl\u00f3rez-Grau","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0445","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad012","article-title":"Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration","volume":"3","author":"Mansilla","year":"2023","journal-title":"Immunother Adv"},{"key":"10.1016\/j.autrev.2026.104120_bb0450","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0460","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4062\/biomolther.2023.006","article-title":"Antigen delivery systems: past, present, and future","volume":"31","author":"Ko","year":"2023","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.autrev.2026.104120_bb0465","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2337\/dbi18-0066","article-title":"The evolving landscape of autoantigen discovery and characterization in type 1 diabetes","volume":"68","author":"Purcell","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0470","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007781","article-title":"Antigen targets of type 1 diabetes autoimmunity","volume":"2","author":"Roep","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0475","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/gut.41.4.565","article-title":"Tissue transglutaminase as the autoantigen of coeliac disease","volume":"41","author":"M\u00e4ki","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104120_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101288","article-title":"The dark side of insulin: a primary autoantigen and instrument of self-destruction in type 1 diabetes","volume":"52","author":"Harrison","year":"2021","journal-title":"Mol Metabol"},{"key":"10.1016\/j.autrev.2026.104120_bb0485","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/dmrr.1250","article-title":"Insulin as a key autoantigen in the development of type 1 diabetes","volume":"27","author":"Nakayama","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.autrev.2026.104120_bb0490","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/imcb.12442","article-title":"Insulin\u2019s other life: an autoantigen in type 1 diabetes","volume":"99","author":"Mannering","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0495","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2337\/dc10-2088","article-title":"Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young","volume":"34","author":"Steck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb0500","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1073\/pnas.1834450100","article-title":"Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse","volume":"100","author":"Moriyama","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104120_bb0505","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI31368","article-title":"Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity","volume":"117","author":"Nakayama","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104120_bb0510","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fendo.2017.00351","article-title":"Understanding autoimmune diabetes through the prism of the tri-molecular complex","volume":"8","author":"Bettini","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104120_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.926650","article-title":"Insulin B-chain hybrid peptides are agonists for T cells reactive to insulin B:9-23 in autoimmune diabetes","volume":"13","author":"Wenzlau","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0520","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jaut.2012.04.005","article-title":"Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading","volume":"39","author":"Prasad","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104120_bb0525","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20030215","article-title":"Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase","volume":"197","author":"Jaeckel","year":"2003","journal-title":"J Exp Med"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2026.104120_bb0530","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.2337\/diabetes.54.suppl_2.S46","article-title":"Dense core vesicle proteins IA-2 and IA-2beta: metabolic alterations in double knockout mice","volume":"54","author":"Kubosaki","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0535","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12026-012-8367-6","article-title":"Type 1 diabetes: primary antigen\/peptide\/register\/trimolecular complex","volume":"55","author":"Sosinowski","year":"2013","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2026.104120_bb0540","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0545","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"Jama"},{"key":"10.1016\/j.autrev.2026.104120_bb0550","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2337\/dc14-2426","article-title":"Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: the environmental determinants of diabetes in the Young (TEDDY)","volume":"38","author":"Steck","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb0555","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-015-3514-y","article-title":"The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study","volume":"58","author":"Krischer","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0560","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00125-025-06573-6","article-title":"Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative","volume":"69","author":"Kuusela","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0565","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1358\/dof.2011.36.11.1710754","article-title":"GAD65 autoantibodies and its role as biomarker of type 1 diabetes and latent autoimmune diabetes in adults (LADA)","volume":"36","author":"Towns","year":"2011","journal-title":"Drugs Future"},{"key":"10.1016\/j.autrev.2026.104120_bb0570","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2013.05.002","article-title":"The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes","volume":"44","author":"Boettler","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104120_bb0575","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.0705894104","article-title":"The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes","volume":"104","author":"Wenzlau","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104120_bb0580","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2016.11.002","article-title":"Long-term GABA administration induces alpha cell-mediated beta-like cell Neogenesis","volume":"168","author":"Ben-Othman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104120_bb0585","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.1073\/pnas.1102715108","article-title":"GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes","volume":"108","author":"Soltani","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104120_bb0590","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.4049\/jimmunol.163.11.6275","article-title":"Determination of glutamic acid decarboxylase 65 peptides presented by the type I diabetes-associated HLA-DQ8 class II molecule identifies an immunogenic peptide motif","volume":"163","author":"Herman","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0595","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2009.02.004","article-title":"Homing of GAD65 specific autoimmunity and development of insulitis requires expression of both DQ8 and human GAD65 in transgenic mice","volume":"33","author":"Elagin","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104120_bb0600","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1083\/jcb.200408172","article-title":"Nuclear translocation of an ICA512 cytosolic fragment couples granule exocytosis and insulin expression in {beta}-cells","volume":"167","author":"Trajkovski","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0605","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1006\/bbrc.1996.1526","article-title":"Molecular cloning and characterization of the human transmembrane protein tyrosine phosphatase homologue, Phogrin, an autoantigen of type 1 diabetes","volume":"227","author":"Kawasaki","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2026.104120_bb0610","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1523\/JNEUROSCI.0101-04.2004","article-title":"Insulinoma-associated protein IA-2, a vesicle transmembrane protein, genetically interacts with UNC-31\/CAPS and affects Neurosecretion in Caenorhabditis elegans","volume":"24","author":"Cai","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.autrev.2026.104120_bb0615","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2337\/db06-0237","article-title":"Crystal structure of the major diabetes autoantigen Insulinoma-associated protein 2 reveals distinctive immune epitopes","volume":"56","author":"Kim","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0620","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00125-025-06382-x","article-title":"IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes","volume":"68","author":"Sims","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0625","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2249.2012.04675.x","article-title":"Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients","volume":"171","author":"Gorus","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0630","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/clinem\/dgac440","article-title":"Index60 is superior to HbA1c for identifying individuals at high risk for type 1 diabetes","volume":"107","author":"Jacobsen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104120_bb0635","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2337\/db18-1351","article-title":"Autoantibodies directed toward a novel IA-2 variant protein enhance prediction of type 1 diabetes","volume":"68","author":"Acevedo-Calado","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0640","first-page":"95","article-title":"IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings","volume":"40","author":"Gorus","year":"1997","journal-title":"Belgian Diabet Regist Diabetol"},{"key":"10.1016\/j.autrev.2026.104120_bb0645","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2337\/dc13-0425","article-title":"The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients","volume":"36","author":"Sosenko","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb0650","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00125-019-04975-x","article-title":"What has zinc transporter 8 autoimmunity taught us about type 1 diabetes?","volume":"62","author":"Williams","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0655","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1242\/jcs.03164","article-title":"In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion","volume":"119","author":"Chimienti","year":"2006","journal-title":"J Cell Sci"},{"key":"10.1016\/j.autrev.2026.104120_bb0660","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10534-005-3687-9","article-title":"ZnT-8, a pancreatic beta-cell-specific zinc transporter","volume":"18","author":"Chimienti","year":"2005","journal-title":"Biometals"},{"key":"10.1016\/j.autrev.2026.104120_bb0665","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ncb951","article-title":"Islet \u03b2-cell secretion determines glucagon release from neighbouring \u03b1-cells","volume":"5","author":"Ishihara","year":"2003","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0670","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2337\/db23-0568","article-title":"Cell-surface ZnT8 antibody prevents and reverses autoimmune diabetes in mice","volume":"73","author":"Kasinathan","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101729","article-title":"Glucose-6-phosphatase catalytic subunit 2 negatively regulates glucose oxidation and insulin secretion in pancreatic \u03b2-cells","volume":"298","author":"Rahim","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2026.104120_bb0680","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1900\/RDS.2007.4.25","article-title":"Endoplasmic reticulum stress caused by overexpression of islet-specific glucose-6-phosphatase catalytic subunit-related protein in pancreatic Beta-cells","volume":"4","author":"Shameli","year":"2007","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.autrev.2026.104120_bb0685","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2337\/diabetes.53.7.1754","article-title":"The proximal islet-specific glucose-6-phosphatase catalytic subunit\u2013related protein autoantigen promoter is sufficient to initiate but not maintain transgene expression in mouse islets in vivo","volume":"53","author":"Frigeri","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0690","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.4049\/jimmunol.176.5.2781","article-title":"Islet-specific Glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human Subjects1","volume":"176","author":"Yang","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0695","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clim.2008.01.015","article-title":"Identification of novel IGRP epitopes targeted in type 1 diabetes patients","volume":"127","author":"Jarchum","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0700","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41586-021-04248-x","article-title":"An autoimmune stem-like CD8 T cell population drives type 1 diabetes","volume":"602","author":"Gearty","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104120_bb0705","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11892-016-0752-4","article-title":"Where, how, and when: positioning posttranslational modification within type 1 diabetes pathogenesis","volume":"16","author":"McLaughlin","year":"2016","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.autrev.2026.104120_bb0710","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2337\/db11-1675","article-title":"Posttranslational modifications of proteins in type 1 diabetes: the next step in finding the cure?","volume":"61","author":"Dunne","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.667989","article-title":"Neoepitopes in type 1 diabetes: etiological insights, biomarkers and therapeutic targets","volume":"12","author":"Rodriguez-Calvo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0720","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2337\/dbi17-0030","article-title":"Immune recognition of \u03b2-cells: Neoepitopes as key players in the loss of tolerance","volume":"67","author":"James","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0725","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.908248","article-title":"Aberrant expression of transglutaminase 2 in pancreas and thymus of NOD mice underscores the importance of deamidation in neoantigen generation","volume":"13","author":"Callebaut","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104120_bb0730","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1021\/acs.jproteome.0c00801","article-title":"Identification of deamidated peptides in cytokine-exposed MIN6 cells through LC-MS\/MS using a shortened digestion time and inspection of MS2 spectra","volume":"20","author":"Callebaut","year":"2021","journal-title":"J Proteome Res"},{"key":"10.1016\/j.autrev.2026.104120_bb0735","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3389\/fimmu.2017.01200","article-title":"Spontaneous secretion of the Citrullination enzyme PAD2 and cell surface exposure of PAD4 by neutrophils","volume":"8","author":"Zhou","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0740","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2337\/db14-0621","article-title":"Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes","volume":"64","author":"Rondas","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0745","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2337\/db20-0421","article-title":"Peptidylarginine deiminase inhibition prevents diabetes development in NOD mice","volume":"70","author":"Sodr\u00e9","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0750","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2337\/db18-0295","article-title":"Inflammation-induced citrullinated glucose-regulated Protein 78 elicits immune responses in human Type 1 diabetes","volume":"67","author":"Buitinga","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0755","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2337\/db13-1952","article-title":"Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes","volume":"63","author":"McGinty","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0760","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41467-022-29512-0","article-title":"Citrullination of glucokinase is linked to autoimmune diabetes","volume":"13","author":"Yang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104120_bb0765","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.coi.2004.09.001","article-title":"Post-translational modifications of self antigens: implications for autoimmunity","volume":"16","author":"Anderton","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0770","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.chembiol.2016.04.006","article-title":"Discovery of phosphorylated Peripherin as a major humoral autoantigen in type 1 diabetes mellitus","volume":"23","author":"Doran","year":"2016","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115927","article-title":"The antigen presentation landscape of cytokine-stressed human pancreatic islets","volume":"44","author":"Nanaware","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104120_bb0780","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2580::AID-IMMU2580>3.0.CO;2-X","article-title":"Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis","volume":"28","author":"Corthay","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0785","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","article-title":"Glycosylation: mechanisms, biological functions and clinical implications","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104120_bb0790","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41423-023-01074-1","article-title":"Immune regulatory networks coordinated by glycans and glycan-binding proteins in autoimmunity and infection","volume":"20","author":"Pinho","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0795","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1007\/s11095-012-0755-z","article-title":"Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via Michael addition to tyrosine oxidation products","volume":"29","author":"Torosantucci","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.autrev.2026.104120_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1537405","article-title":"The role of oxidative post-translational modifications in type 1 diabetes pathogenesis","volume":"16","author":"Alhamar","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0805","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.aad2791","article-title":"Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion","volume":"351","author":"Delong","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.autrev.2026.104120_bb0810","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.667870","article-title":"Identifying new hybrid insulin peptides (HIPs) in type 1 diabetes","volume":"12","author":"Mannering","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0815","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ni.1844","article-title":"Chromogranin A is an autoantigen in type 1 diabetes","volume":"11","author":"Stadinski","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0820","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2013.10.003","article-title":"Chromogranin A is a T cell antigen in human type 1 diabetes","volume":"50","author":"Gottlieb","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104120_bb0825","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/acs.jproteome.8b00875","article-title":"Identification of hybrid insulin peptides (HIPs) in mouse and human islets by mass spectrometry","volume":"18","author":"Wiles","year":"2019","journal-title":"J Proteome Res"},{"key":"10.1016\/j.autrev.2026.104120_bb0830","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.2337\/db18-0200","article-title":"CD4 T cells reactive to hybrid insulin peptides are indicators of disease activity in the NOD mouse","volume":"67","author":"Baker","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.autrev.2026.104120_bb0835","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2337\/db25-0324","article-title":"Strategic reduction of hybrid insulin peptide formation significantly delays diabetes onset in NOD mice","volume":"75","author":"Groegler","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0840","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.2337\/db19-0128","article-title":"Hybrid insulin peptides are autoantigens in type 1 diabetes","volume":"68","author":"Baker","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0845","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/ng.259","article-title":"Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing","volume":"40","author":"Pan","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2026.104120_bb0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002552","article-title":"The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines","volume":"8","author":"Eizirik","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.autrev.2026.104120_bb0855","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s00125-023-05882-y","article-title":"Presence of immunogenic alternatively spliced insulin gene product in human pancreatic delta cells","volume":"66","author":"van Tienhoven","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0860","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1530\/EJE-15-0916","article-title":"Mechanisms in endocrinology: alternative splicing: the new frontier in diabetes research","volume":"174","author":"Juan-Mateu","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2026.104120_bb0865","doi-asserted-by":"crossref","first-page":"11818","DOI":"10.1093\/nar\/gku861","article-title":"Nova1 is a master regulator of alternative splicing in pancreatic beta cells","volume":"42","author":"Villate","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.autrev.2026.104120_bb0870","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1189\/jlb.1113599","article-title":"Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors","volume":"95","author":"Ant\u00f3n","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2026.104120_bb0875","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2337\/db20-1122","article-title":"Long RNA sequencing and ribosome profiling of inflamed \u03b2-cells reveal an extensive translatome landscape","volume":"70","author":"Thomaidou","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0880","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm.4289","article-title":"Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes","volume":"23","author":"Kracht","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0885","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00125-023-05991-8","article-title":"IFN\u0263 but not IFN\u03b1 increases recognition of insulin defective ribosomal product-derived antigen to amplify islet autoimmunity","volume":"66","author":"Thomaidou","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0890","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41590-025-02343-z","article-title":"A microenvironment-driven HLA-II-associated insulin neoantigen elicits persistent memory T cell activation in diabetes","volume":"27","author":"Srivastava","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0895","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fimmu.2018.00392","article-title":"Peptide immunotherapy for type 1 diabetes-clinical advances","volume":"9","author":"Smith","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0900","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1023264","article-title":"Preventing type 1 diabetes in late-stage pre-diabetic NOD mice with insulin: a central role for alum as adjuvant","volume":"13","author":"Martens","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104120_bb0905","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","article-title":"Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial--Type 1","volume":"28","author":"Skyler","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb0910","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/dc17-0806","article-title":"Type 1 diabetes TrialNet: a multifaceted approach to bringing disease-modifying therapy to clinical use in type 1 diabetes","volume":"41","author":"Bingley","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb0915","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/S0140-6736(08)61309-4","article-title":"Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial","volume":"372","author":"N\u00e4nt\u00f6-Salonen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104120_bb0920","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2017.17070","article-title":"Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial","volume":"318","author":"Krischer","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2026.104120_bb0925","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00125-020-05376-1","article-title":"Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial","volume":"64","author":"Assfalg","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb0930","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc24-0573","article-title":"Oral insulin delay of stage 3 type 1 diabetes revisited in HLA DR4-DQ8 participants in the TrialNet Oral insulin prevention trial (TN07)","volume":"47","author":"Zhao","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb0935","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/MED.0000000000000648","article-title":"Insulin immunotherapy for pretype 1 diabetes","volume":"28","author":"Jacobsen","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.autrev.2026.104120_bb0940","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028578","article-title":"Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol","volume":"9","author":"Ziegler","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2026.104120_bb0945","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/S0140-6736(25)01726-X","article-title":"Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial","volume":"406","author":"Ziegler","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104120_bb0950","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12916-023-02900-z","article-title":"First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes","volume":"21","author":"Van Rampelbergh","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0955","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12916-024-03476-y","article-title":"First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers","volume":"22","author":"Van Rampelbergh","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0960","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc24-1832","article-title":"A randomized trial comparing inhaled insulin plus basal insulin versus usual care in adults with Type 1 diabetes","volume":"48","author":"Hirsch","year":"2025","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1016\/j.autrev.2026.104120_bb0965","article-title":"Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices","volume":"12","author":"Becker","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.autrev.2026.104120_bb0970","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.4049\/jimmunol.174.8.4516","article-title":"Active tolerance induction and prevention of autoimmune diabetes by Immunogene therapy using recombinant Adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD500\u20135851","volume":"174","author":"Han","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb0975","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/pedi.12611","article-title":"Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial","volume":"19","author":"Larsson","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb0980","volume":"12","author":"Ludvigsson","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2026.104120_bb0985","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa0804328","article-title":"GAD treatment and insulin secretion in recent-onset type 1 diabetes","volume":"359","author":"Ludvigsson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0990","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104120_bb0995","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104120_bb1000","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00125-005-1802-7","article-title":"Vitamin D and diabetes","volume":"48","author":"Mathieu","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb1005","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2337\/db21-0728","article-title":"Immune and metabolic effects of antigen-specific immunotherapy using multiple \u03b2-cell peptides in type 1 diabetes","volume":"71","author":"Liu","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb1010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jconrel.2024.09.020","article-title":"LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice","volume":"375","author":"Chen","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.autrev.2026.104120_bb1015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaut.2018.11.003","article-title":"A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in type 1 diabetes","volume":"98","author":"Postigo-Fernandez","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104120_bb1020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006103","article-title":"Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes","volume":"5","author":"Roep","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104120_bb1025","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2337\/db15-1625","article-title":"Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting Lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells","volume":"66","author":"Takiishi","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb1030","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2337\/db22-0852","article-title":"A plasma miR-193b-365 signature combined with age and glycemic status predicts response to Lactococcus lactis-based antigen-specific immunotherapy in new-onset type 1 diabetes","volume":"72","author":"Sassi","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb1035","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.2337\/db13-1236","article-title":"Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice","volume":"63","author":"Robert","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb1040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-023-06014-2","article-title":"A first-in-human, open-label phase 1b and a randomised, double-blind phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab","volume":"67","author":"Mathieu","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb1045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cei\/uxac115","article-title":"Antigen-specific immunotherapy to restore antigen-specific tolerance in type 1 diabetes and graves\u2019 disease","volume":"211","author":"Zala","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb1050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.actbio.2025.06.016","article-title":"Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin delivery","volume":"201","author":"Pang","year":"2025","journal-title":"Acta Biomater"},{"key":"10.1016\/j.autrev.2026.104120_bb1055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4049\/jimmunol.2200208","article-title":"Tolerogenic immune-modifying nanoparticles encapsulating multiple recombinant pancreatic \u03b2 cell proteins prevent onset and progression of type 1 diabetes in nonobese diabetic mice","volume":"209","author":"Podojil","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb1060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.immuni.2010.03.015","article-title":"Reversal of autoimmunity by boosting memory-like autoregulatory T cells","volume":"32","author":"Tsai","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104120_bb1065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104120_bb1070","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac002","article-title":"Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes","volume":"2","author":"Tatovic","year":"2022","journal-title":"Immunother Adv"},{"key":"10.1016\/j.autrev.2026.104120_bb1075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127057","article-title":"Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes","volume":"10","author":"Pujol-Autonell","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104120_bb1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103196","article-title":"Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes","volume":"145","author":"Garcia-Loza","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104120_bb1085","doi-asserted-by":"crossref","first-page":"18927","DOI":"10.1038\/s41598-020-76041-1","article-title":"Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes","volume":"10","author":"Villalba","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104120_bb1090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1172\/JCI115946","article-title":"Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer","volume":"90","author":"Clare-Salzler","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104120_bb1095","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.4049\/jimmunol.173.7.4331","article-title":"Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells","volume":"173","author":"Machen","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb1100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.celrep.2015.01.013","article-title":"Vitamin D3 induces tolerance in human dendritic cells by activation of intracellular metabolic pathways","volume":"10","author":"Ferreira","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104120_bb1105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jcyt.2020.12.003","article-title":"1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic tolerogenic dendritic cells with specific epigenetic modifications","volume":"23","author":"van Megen","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.autrev.2026.104120_bb1110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1054968","article-title":"Tolerogenic dendritic cells pulsed with islet antigen induce long-term reduction in T-cell autoreactivity in type 1 diabetes patients","volume":"13","author":"Nikolic","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb1115","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb1120","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S2213-8587(20)30104-2","article-title":"Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide\u2014for type 1 diabetes","volume":"8","author":"Nikolic","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.autrev.2026.104120_bb1125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.171844","article-title":"GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes","volume":"9","author":"Uenishi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2026.104120_bb1130","article-title":"Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104120_bb1135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"10.1016\/j.autrev.2026.104120_bb1140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaut.2009.10.005","article-title":"Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy","volume":"34","author":"Orban","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104120_bb1145","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMc1616343","article-title":"Intralymphatic injection of autoantigen in type 1 diabetes","volume":"376","author":"Ludvigsson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104120_bb1150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010374","article-title":"Redosing with Intralymphatic GAD-alum in the treatment of type 1 diabetes: the DIAGNODE-B pilot trial","volume":"26","author":"Casas","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104120_bb1155","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00125-020-05227-z","article-title":"Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes","volume":"63","author":"Hannelius","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb1160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dc19-0880","article-title":"Introducing the Endotype concept to address the challenge of disease heterogeneity in type 1 diabetes","volume":"43","author":"Battaglia","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb1165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112858","article-title":"The need and benefit of immune monitoring to define patient and disease heterogeneity, mechanisms of therapeutic action and efficacy of intervention therapy for precision medicine in type 1 diabetes","volume":"14","author":"Roep","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb1170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature14452","article-title":"Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation","volume":"523","author":"Gagliani","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104120_bb1175","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071081","article-title":"Designing personalized antigen-specific immunotherapies for autoimmune diseases-the case for using ignored target cell antigen determinants","volume":"11","author":"Tian","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2026.104120_bb1180","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202200135","article-title":"Delivery route considerations for designing antigen-specific biomaterial strategies to combat autoimmunity","volume":"3","author":"Ackun-Farmmer","year":"2023","journal-title":"Adv Nanobiomed Res"},{"key":"10.1016\/j.autrev.2026.104120_bb1185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142242","article-title":"Type 1 diabetes mellitus: much progress, many opportunities","volume":"131","author":"Powers","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104120_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101809","article-title":"The beta cell-immune cell interface in type 1 diabetes (T1D)","volume":"78","author":"James","year":"2023","journal-title":"Mol Metab"},{"key":"10.1016\/j.autrev.2026.104120_bb1195","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00125-023-05970-z","article-title":"Islet autoimmunity in human type 1 diabetes: initiation and progression from the perspective of the beta cell","volume":"66","author":"Thompson","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb1200","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s13340-024-00748-z","article-title":"Type 1 diabetes: immune pathology and novel therapeutic approaches","volume":"15","author":"Ling","year":"2024","journal-title":"Diabetol Int"},{"key":"10.1016\/j.autrev.2026.104120_bb1205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730414","article-title":"Overcoming obstacles in the development of antigen-specific immunotherapies for type 1 diabetes","volume":"12","author":"Thomas","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb1210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/pedi.13300","article-title":"Heterogeneity in the presentation of clinical type 1 diabetes defined by the level of risk conferred by human leukocyte antigen class II genotypes","volume":"23","author":"Taka","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.autrev.2026.104120_bb1215","series-title":"Book Genetic association of T1D stratified by HLA DR3 and DR4 status reveals heterogeneity in pathways of progression to T1D","article-title":"Genetic association of T1D stratified by HLA DR3 and DR4 status reveals heterogeneity in pathways of progression to T1D","author":"Luckett","year":"2025"},{"key":"10.1016\/j.autrev.2026.104120_bb1220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2337\/dc19-0803","article-title":"Genetic variants predisposing most strongly to type 1 diabetes diagnosed under age 7 years lie near candidate genes that function in the immune system and in pancreatic \u03b2-cells","volume":"43","author":"Inshaw","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb1225","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3770","article-title":"Type 1 diabetes: a new vision of the disease based on endotypes","volume":"40","author":"Weston","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.autrev.2026.104120_bb1230","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/dci25-0013","article-title":"The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment-2024 diabetes, diabetes care, and Diabetologia expert forum","volume":"48","author":"Evans-Molina","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb1235","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041602","article-title":"Integrating omics into functional biomarkers of type 1 diabetes","volume":"14","author":"Long","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.autrev.2026.104120_bb1240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd5666","article-title":"Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression","volume":"13","author":"Xhonneux","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104120_bb1245","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176403","article-title":"Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes","volume":"135","author":"Sassi","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104120_bb1250","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jprot.2017.10.004","article-title":"Temporal expression profiling of plasma proteins reveals oxidative stress in early stages of type 1 diabetes progression","volume":"172","author":"Liu","year":"2018","journal-title":"J Proteomics"},{"key":"10.1016\/j.autrev.2026.104120_bb1255","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12902-024-01679-1","article-title":"Lipid profile alterations and biomarker identification in type 1 diabetes mellitus patients under glycemic control","volume":"24","author":"Cai","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.autrev.2026.104120_bb1260","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41390-022-02448-3","article-title":"The methylome and cell-free DNA: current applications in medicine and pediatric disease","volume":"94","author":"Spector","year":"2023","journal-title":"Pediatr Res"},{"key":"10.1016\/j.autrev.2026.104120_bb1265","doi-asserted-by":"crossref","first-page":"19018","DOI":"10.1073\/pnas.1111008108","article-title":"Detection of \u03b2 cell death in diabetes using differentially methylated circulating DNA","volume":"108","author":"Akirav","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104120_bb1270","article-title":"Recent advances in early diagnosis and treatment of T1D with miRNAs","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.autrev.2026.104120_bb1275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112843","article-title":"miRNAs as biomarkers in diabetes: moving towards precision medicine","volume":"23","author":"Angelescu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104120_bb1280","article-title":"A set of circulating microRNAs belonging to the 14q32 chromosome locus identifies two subgroups of individuals with recent-onset type 1 diabetes","volume":"5","author":"Sebastiani","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.autrev.2026.104120_bb1285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trsl.2018.07.009","article-title":"Serum biomarkers for diagnosis and prediction of type 1 diabetes","volume":"201","author":"Yi","year":"2018","journal-title":"Transl Res"},{"key":"10.1016\/j.autrev.2026.104120_bb1290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1158278","article-title":"The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness","volume":"14","author":"Fyvie","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104120_bb1295","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Low-dose anti-Thymocyte globulin (ATG) preserves \u03b2-cell function and improves HbA(1c) in new-onset type 1 diabetes","volume":"41","author":"Haller","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2026.104120_bb1300","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2023.2064","article-title":"Effect of verapamil on pancreatic Beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial","volume":"329","author":"Forlenza","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2026.104120_bb1305","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00125-025-06490-8","article-title":"Verapamil and low-dose anti-mouse thymocyte globulin combination therapy stably reverses recent-onset type 1 diabetes in NOD mice by acting on the beta cell and immune axes","volume":"68","author":"Degroote","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2026.104120_bb1310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12575-025-00307-z","article-title":"CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored","volume":"27","author":"Pattanaik","year":"2025","journal-title":"Biol Proced Online"},{"key":"10.1016\/j.autrev.2026.104120_bb1315","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s42255-022-00531-x","article-title":"Single-cell multi-omics analysis of human pancreatic islets reveals novel cellular states in type 1 diabetes","volume":"4","author":"Fasolino","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.autrev.2026.104120_bb1320","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s43856-025-00922-7","article-title":"A multi-omics integration approach relying on circulating factors does not discern subtypes of childhood type 1 diabetes","volume":"5","author":"Codazzi","year":"2025","journal-title":"Commun Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:02:51Z","timestamp":1786071771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":264,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1568997226001345"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104120","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigen-specific tolerance therapies in type 1 diabetes: Disease-specific promises meet stage-specific challenges","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104120"}}